###begin article-title 0
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Mutation spectrum of CYP1B1 in North Indian congenital glaucoma patients
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
Mutations in Cytochrome P450 (CYP1B1) are a predominant cause of congenital glaucoma. This study was planned with the aim to identify the mutation profile of CYP1B1 in North Indian primary congenital glaucoma (PCG) patients.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 191 197 191 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
After ethical clearance, 50 congenital glaucoma patients and 50 ethnically matched controls were recruited in this study. Genomic DNA was isolated from the blood and trabecular meshwork, and CYP1B1 was screened for the six most prevalent mutations (termination at 223 [Ter@223], Gly61Glu, Pro193Leu, Glu229Lys, Arg368His, and Arg390Cys) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). DNA sequencing was done to identify other mutations and for confirmation of RFLP positive samples.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYPIB1</italic>
###xml 739 745 739 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
On PCR-RFLP, 21/50 cases (42%) were found positive for one or more of these mutations. However, on sequencing, we found that 23/50 (46%) harbored the CYPIB1 mutations. Ter@223 was found in 18%, p.R390H in 16%, and p.R368H in 8% of cases. Three novel mutations, p.L24R, p.F190L, and p.G329D, were identified by DNA sequencing. Leucine, phenylalanine, and glycine are conserved at the 24th, 190th, and 329th position in the CYP1B1 protein in different species, suggestive of important functions at these loci. Ter@223 was found to be the most prevalent mutation in our patients while p.R368H was most prevalent in southern India. The difference in frequency and mutation profile may be due to the heterogeneous Indian population. Pathogenic CYP1B1 mutations impair anterior chamber development and differentiation by blocking the aqueous outflow and raising intraocular pressure (IOP).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Three novel mutations were identified in this study. Studies of pathogenic sequence variants in CYP1B1 in different populations may contribute to a better understanding of the disease pathogenesis. This may lead to the development of novel therapeutic approaches in the near future.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 748 749 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 1327 1328 1327 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 1392 1393 1392 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 1429 1430 1429 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 1512 1513 1512 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 1810 1815 <span type="species:ncbi:9606">child</span>
Primary congenital glaucoma (PCG; ; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD) is an inherited ocular disorder of the trabecular meshwork and anterior chamber angle. This leads to the impairment of aqueous outflow, increased intraocular pressure (IOP), and optic nerve damage that can result in permanent vision loss. The term PCG is reserved for those cases in which the only anatomic defect observed is isolated trabeculodysgenesis. It is the second largest cause of blindness, accounting for 15% of cases of blindness. The disease manifests in the neonatal or early infantile period with symptoms of enlargement of the globe, opacification of the cornea, and breaks in Descemet's membrane [1]. It is characterized by the loss of retinal ganglion cells which leads to irreversible blindness. It is bilateral in 80% of cases. More than 80% of cases present within first year of life out of which the disease is diagnosed in the neonatal period in 25% of the cases and within the first six months of life in 60% of cases. PCG accounts for 55% of primary pediatric glaucoma and is the most common type. Its expression and penetrance varies from 40% to 100%. The prevalence of PCG varies across ethnic communities ranging from 1 in 10,000-20,000 in the western populations [2] to 1 in 2,500 and 1 in 1,250 in the Saudi Arabian population [3] and Gypsy population of Slovakia [2], respectively. In the Indian state of Andhra Pradesh, prevalence is 1 in 3,300 [4]. The high incidence in the eastern countries is thought to be due to consanguineous marriages. Early and reliable diagnosis of the disease is vital, so that appropriate and prompt medical and surgical interventions can be initiated. This could in turn prevent visual loss and save vision of the child.
###end p 11
###begin p 12
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 799 805 799 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 845 851 845 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 962 968 962 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 1238 1244 1238 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Although there has been much progress in finding new genes and detecting disease-related mutations, little is known about the function of the mutated gene products and the underlying pathogenic mechanisms. Further, it is estimated that all the known loci/genes of glaucoma account for the minority of total cases of glaucoma, and hence, many other genes remain to be identified. Even though three different loci have been mapped for PCG [5,6], mutations in Cytochrome P450 (CYP1B1; GLC3A) are the most predominant cause of disease [7] and are reported in various ethnic backgrounds [7-10]. An additional PCG locus, GLC3B [6], has been mapped to the short arm of chromosome 1 and a third locus, GLC3C, to 14q24.3, but these genes have not been identified. Recently, studies showed the association of CYP1B1 with PCG in the Indian population [8]. CYP1B1 is located on chromosome 2 at position p21. The gene contains three exons and two introns. The three exons of CYP1B1 are 371, 1,044, and 3,707 base pairs in length, and the two introns are 390 and 3032 base pairs in length. Both introns begin with the sequence GT and end with the sequence AG. The regions upstream of the 3' end of the introns are pyrimidine rich. The coding region of CYP1B1 starts at the 5' end of the second exon and ends within the third exon. The putative open reading frame is 1,629 base pairs in length and codes for a 543 amino acid protein.
###end p 12
###begin p 13
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 379 385 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
Although genetic heterogeneity has been reported in PCG, homogeneity in phenotype as well as genotype (p.E387K) has been reported in the Slovak Gypsy population, and common haplotypes (p.G61E, p.D374N, and p.R469W) have been associated in the Saudi Arabian population [9,10]. Confirmation of linkage between CYP1B1 and PCG in different populations have verified the GLC3A locus (CYP1B1) as a major cause of PCG accounting for 85%-90% of all familial cases and 27% of sporadic cases. CYPIB1-deficient mice exhibit similar abnormalities in their trabecular meshwork similar to those in PCG patients.
###end p 13
###begin p 14
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 203 211 203 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 794 800 794 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 857 863 857 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 141 147 <span type="species:ncbi:9606">people</span>
###xml 1041 1049 <span type="species:ncbi:9606">patients</span>
To date there are very few studies regarding CYP1B1 mutations in PCG patients from northern India. India has a heterogeneous population with people from north and south India being ethnically different (Figure 1). The  composition of the population of India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka mostly falls within two large groups, Dravidian and Indo-Aryan. These groups are further subdivided into numerous sub-groups, castes, and tribes. Indo-Aryans form the predominant ethno-linguistic group in Pakistan, India (the central, eastern, western, and northern regions), Nepal, Sri Lanka, and the Maldives. Dravidians form the predominant ethno-linguistic group in southern India and the northern and eastern regions of Sri Lanka [11]. To study the mutation profile of CYP1B1 causing PCG in the north Indian population, we screened CYP1B1 in 50 new and unrelated cases of north Indian ethnic background. The data from this preliminary study helped us to understand the common mutations prevalent in North Indian PCG patients, however larger studies are required to establish a genotype/phenotype correlation.
###end p 14
###begin p 15
Map of India showing distribution of different ethnic populations in different parts of the country.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Clinical examination and selection of cases
###end title 17
###begin p 18
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
After approval from the institutional review board (IRB # IRB00006862; All India Institute of Medical Sciences, Delhi, India), 50 consecutively diagnosed congenital glaucoma cases from northern India, presenting at the Dr. R. P. Centre for Ophthalmic Sciences (AIIMS, New Delhi, India), were enrolled for this study. The diagnosis involved clinical ocular and systemic examination. All patients underwent ophthalmoscopy and tonometry during the screening. Inclusion criteria of the patients were increased corneal diameter (>12.0 mm), raised intraocular pressure (>21 mmHg) with presence or absence of Haab's striae and  optic disc changes (where examination was possible). Symptoms of epiphora and photophobia were the additional inclusion factors. The age of onset ranged from birth to one year. All cases were sporadic without any history of glaucoma. Fifty ethnically matched normal individuals without any history of ocular disorders were enrolled as controls. Peripheral blood samples were collected from the probands, their relatives, and controls by venipuncture after informed consent.
###end p 18
###begin title 19
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Screening of CYP1B1
###end title 19
###begin p 20
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 808 809 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 452 460 <span type="species:ncbi:9606">patients</span>
Genomic DNA was isolated from the blood and trabecular tissue by the phenol chloroform method. The DNA isolation kit (Genomic DNA Mini Kit, #GB100; Geneaid Biotech Ltd., Sijhih City, Taiwan) was used in cases with less sample (<1 ml). Mutations in CYP1B1 are the predominant cause of PCG. The entire coding region (1.6 kb organized in exons II and III) was screened for mutations. Using three sets of overlapping primers [8], CYP1B1 was amplified from patients and control subjects. Mutation screening was done using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) followed by PCR-DNA sequencing. PCR-RFLP was done for rapid detection of the six most prevalent mutations: p.G61E, p.P193L, p.Ter@223, p E229K, p.R368H, and p.R390C according to the protocol described previously [8]. DNA sequencing was done in all cases to identify all nucleotide changes like single nucleotide polymorphisms (SNPs) and mutations.
###end p 20
###begin title 21
PCR-RFLP analyses and cosegregation of mutant alleles with disease phenotype
###end title 21
###begin p 22
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
In all RFLP-positive cases, mutations resulted in either loss or gain of restriction site. For determining the cosegregation of mutant alleles with disease phenotype in the families, the respective fragments harboring the mutation were amplified from all available family members and RFLP was done as previously described [8]. The fragments were separated on 2% agarose gel, stained with ethidium-bromide, and visualized in ultraviolet light to distinguish the wild type and mutant alleles. DNA sequencing was done to confirm the mutation.
###end p 22
###begin title 23
PCR-DNA sequencing
###end title 23
###begin p 24
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYPB1</italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 680 681 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 151 158 <span type="species:ncbi:9606">patient</span>
The whole coding region of CYPB1 was amplified in all cases using already published primers [12,13], and amplicons were sequenced bidirectionally. The patient and control sequences were then compared to identify all mutations. The primers used were set I (1F-1R, 786 bp) [12], set II (2F-2R, 787 bp) [13], and set III (3F-3R, 885 bp) [12]. All PCRs were performed for only 30 cycles, and conditions for sets I and II were as reported earlier [12] while conditions for set III were initial denaturation at 94 degreesC for 3 min followed by 30 cycles each at 94 degreesC for 30 s, 60 degreesC for 30 s, and 72 degreesC for 1 min. PCR was done using previously described conditions [8].
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
PCR-RFLP analysis of six most prevalent pathogenic mutations
###end title 26
###begin p 27
###xml 386 386 376 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 513 515 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
###xml 604 612 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
PCR-RFLP analyses were performed for all six mutations (376insA, 528G-->A, 923C-->T, 959G-->A, 1449G-->A, and 1514C-->T). Out of 50 patients, 21 were found positive (homozygous/heterozygous) for one or more of the above mentioned mutations. All PCR-RFLP-positive samples were subsequently sequenced to confirm the mutation. Both p.R390C and p.R390H removed the restriction site for Hin6restriction enzyme, and DNA sequencing confirmed p.R390H in our patients, which has also been reported from Pakistan and Iran [13]. Among the six mutations screened, p.Ter@223 was the predominant disease allele in our patients and 18% of the patients were found to be heterozygous or homozygous for this mutation. The R390H mutation (16%) was the next dominant disease allele. Compound heterozygosity was observed in 10% of the cases (5/50).
###end p 27
###begin title 28
Identification of three novel missense mutations and one neutral mutation
###end title 28
###begin title 29
Leucine24Arginine*-Novel mutation
###end title 29
###begin p 30
###xml 224 232 224 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
One patient (PCG 022) harbored a novel homozygous missense mutation, p. L24R (GenBank ), in which the nucleotide thymine (T) was replaced by guanine (G) at genomic position 38159965 and nucleotide position 1432 in the gene (Figure 2). This resulted in a codon change from CTG to CGG in which a nonpolar amino acid leucine was replaced by a basic amino acid arginine at position 24 in the polypeptide.
###end p 30
###begin p 31
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 62 63 62 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
DNA sequence from exon 2 of CYP1B1 equivalent to codon 22-26. A: The reference sequence derived from the control is shown. B: The sequence derived from PCG 022 shows the homozygous T>G mutation at genomic position 38159965, which predicts a codon change from CTG to CGG and L24R mutation.
###end p 31
###begin title 32
Phenylalanine190Leucine*-Novel mutation
###end title 32
###begin p 33
###xml 172 180 172 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 428 435 <span type="species:ncbi:9606">patient</span>
One patient (PCG 042) DNA sequencing revealed a change of the nucleotide cytosine (C) to adenine (A) at genomic position 38155466 and nucleotide position 1931 in the gene (Figure 3). This produced a codon change from TTC to TTA resulting in p. F190L, a novel missense mutation (GenBank ) replacing amino acid phenylalanine with leucine. This mutation was found in association with the p. R368H mutation (homozygous) in the same patient.
###end p 33
###begin p 34
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 65 66 65 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 122 123 122 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
DNA sequence from exon 2 of CYP1B1 equivalent to codon  187-191. A: The reference sequence derived from control is shown. B: The sequence derived from PCG 042 shows the homozygous C>A mutation at genomic position 38155466, which predicts a codon change from TTC to TTA and the F190L mutation.
###end p 34
###begin title 35
Glycine329Aspartic acid*-Novel mutation
###end title 35
###begin p 36
###xml 181 189 181 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 8 15 <span type="species:ncbi:9606">patient</span>
Another patient (PCG 043) DNA sequencing revealed a substitution of the nucleotide guanine (G) by adenine (A) at genomic position 38155050 and nucleotide position 2347 in the gene (Figure 4), which resulted in a codon change from GGC to GAC replacing amino acid glycine at position 329 with aspartic acid. This resulted in a novel missense mutation, p. G329D (GenBank ).
###end p 36
###begin p 37
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 67 68 67 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 124 125 124 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
DNA sequence from exon 2nd of CYP1B1 equivalent to codon  328-331. A: Reference sequence derived from control is displayed. B: The sequence derived from PCG 043 shows the heterozygous G>A mutation at genomic position 38155050, which predicts a codon change from GGC to GAC and the G329D mutation.
###end p 37
###begin title 38
Leucine298Leucine
###end title 38
###begin p 39
###xml 211 218 211 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 11 18 <span type="species:ncbi:9606">patient</span>
In another patient (PCG 003), cytosine (C) was substituted by thymine (T), which changed codon CTC to CTT. This resulted in a synonymous mutation with no amino acid change. Details of all mutations are given in Table 1.
###end p 39
###begin title 40
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Details of all CYP1B1 mutations.
###end title 40
###begin p 41
The age of onset for all individuals was by birth. Abbreviations; H: Homozygous mutation; h: heterozygous mutation; OD-right eye; OS-left eye; OU-both eyes; X-times; Trab/Trab, combined trabeculotomy and trabeculectomy; PK-penetrating keratoplasty; NPL-no perception of light; NA-not available.
###end p 41
###begin title 42
Other previously reported mutations
###end title 42
###begin title 43
Missense mutations
###end title 43
###begin p 44
###xml 346 353 346 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 411 419 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
Eight patients were identified with p.R390H (five homozygous and three heterozygous), four with p.R368H (two homozygous and two heterozygous), nine with Ter@223 (one homozygous and eight heterozygous), five with p.E229K (all heterozygous) mutations, and one with a p.M132R homozygous mutation. Out of these, four patients had compound mutations (Table 1). The heterozygous p.E229K mutation was detected in five patients in our study, and Panicker et al. [8] also reported a similar mutation in heterozygous state in PCG patients.
###end p 44
###begin title 45
Compound heterozygous mutation
###end title 45
###begin p 46
###xml 4 12 <span type="species:ncbi:9606">patients</span>
Two patients (PCG 034 and PCG 041) were compound heterozygotes for R390H and Ter@223 mutations, one (PCG 039) was heterozygous for p.R368H and p.Ter@223 mutations, and two (PCG 036, 045) had p.E229K and p.R390H mutations.
###end p 46
###begin title 47
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Nonpathogenic CYP1B1 single nucleotide polymorphisms
###end title 47
###begin p 48
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 314 322 312 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5</xref>
###xml 398 404 396 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
In addition to pathogenic mutations, six already reported single nucleotide polymorphisms [8] were identified in the less conserved region of CYP1B1 both in the controls and patients. These polymorphisms were p.R48G, p.A119S, p.L432V, p.D449D, p.N453S, and . They were revealed by DNA sequencing.  (38156104C-->T; Figure 5) was identified in two patients (PCG 039 and PCG 040). All patients with a CYP1B1 mutation also had L432V polymorphism. These polymorphisms were present in controls.
###end p 48
###begin p 49
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 49 50 49 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 104 105 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
DNA sequence from intron 1 and exon 2 of CYP1B1. A: Reference sequence derived from a control is shown. B: DNA sequence derived from PCG 040 shows the homozygous C>T (38156048C-->T) nucleotide change, an already reported polymorphism ().
###end p 49
###begin p 50
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
On sequencing, pathogenic CYP1B1 mutations were identified in 23 patients (46%) but not in controls.
###end p 50
###begin title 51
Structural and functional implications of mutant proteins
###end title 51
###begin title 52
Leucine24Arginine (P. L24R)
###end title 52
###begin p 53
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 321 329 321 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
###xml 211 216 <span type="species:ncbi:9606">human</span>
The first 49 residues from the NH2-terminal end and the last 16 residues at the COOH-terminal (residues 528-543) in CYP1B1 did not have corresponding equivalent regions in CYP2c9 from where the structure of the human CYP1B1 protein was determined [14]. Leucine is conserved in the CYP1B1 protein among different species (Figure 6). Thus, we can hypothesize that leucine plays an important role in determining the structure and thus function of this protein.
###end p 53
###begin p 54
###xml 84 87 84 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Red</bold>
Multiple sequence alignment of various members of the cytochrome P450 super-family. Red letters indicate the conserved residues, which cause the congenital glaucoma phenotype when mutated.
###end p 54
###begin title 55
Methionine132Arginine (M132R)
###end title 55
###begin p 56
###xml 264 265 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
The mutation site lies in the heme-binding region (HBR), which bridges helices B' and C. In the wild type protein, methionine extends in the interior and packs between the I-helix (between N-319 and Y-349) and one of the heme propionate groups. The amino group (NH2) of M-132 donates a hydrogen bond (hb) to D-326 of the I-helix and accepts a hb from G-135, W-141, and R-468, thus interconnecting the I-helix, C-helix, and heme binding loop (HBL) [15]. Replacement of methionine by arginine leads to congestion of this packing, thereby potentially harming the H-bond interaction.
###end p 56
###begin title 57
Phenylalanine190Leucine (F190L)
###end title 57
###begin p 58
###xml 143 151 143 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
The amino acid at position 190 lies between the alpha helix D and E. Phenylalanine is conserved in the CYP1B1 protein among different species (Figure 6). Phenylalanine contains an aromatic ring while leucine contains an aliphatic group. So this amino acid substitution may lead to structural alterations in the CYP1B1 protein.
###end p 58
###begin title 59
Termination@223
###end title 59
###begin p 60
###xml 411 412 411 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
In this mutation, nucleotide A is inserted in the cDNA at position 376, resulting in a frame-shift that truncates the open reading frame (ORF) by creating a premature stop codon (TGA) 636 bp downstream from the insertion site. Consequently, a 222 amino acid protein is produced, which lacks 321 amino acids from the COOH-terminal. Both the wild type and the mutant proteins contain just 10 amino acids at the NH2-terminus, which are similar in both, and the frame-shift eliminated all CYP1B1 domains, resulting in a functionally null allele [8].
###end p 60
###begin title 61
Glutamic acid 229Lysine (E229K)
###end title 61
###begin p 62
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 743 745 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
Position 229 lies in a key region, contributing to the three-dimensional structure of the protein [15]. This mutation occurs in the COOH-terminal of the F-helix in the vicinity of the substrate binding region (SBR). Substitution of E to K leads to a change from a negatively charged residue to a positively charged side chain and this in turn affects the local charge distribution. This mutation disturbs an important cluster of salt bridges. In wild type (WT), R-194::E-229, R-194::D-333, and D-333::K-512 form a triangle of ionic bond interactions, holding I-helix with F-helix and beta-strand S3.2. Due to this mutation, the R-194::E-229 interaction is lost and has the potential to destabilize the other ionic interactions in the protein [15].
###end p 62
###begin title 63
Glycine329Aspartic acid (G329D)
###end title 63
###begin p 64
###xml 87 95 87 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 188 189 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
Gly329 is located in the conserved I-helix of the CYP1B1 protein in different species (Figure 6). Glycine is the smallest and most simple amino acid whereas aspartic acid contains a CH2COO- acidic group. Replacement of glycine by aspartic acid may cause conformational changes in the protein. Ala330Phe was the first missense mutation reported in this domain [16]. This mutation represents the second missense mutation detected in this domain.
###end p 64
###begin title 65
Arginine368Histidine (R368H)
###end title 65
###begin p 66
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
The residue lies in between the helices J and K in an exposed loop [1,8,17]. Consequences of this change are not immediately apparent except that the positively charged amino acid arginine is replaced by histidine whose charge state depends upon its protonation state. In the WT, arginine at 368 interacts with G-365, D-367, V-363, and D-374. Because of the R368H mutation, interactions between D-367 and D-374 are weakened. How this affects the conformation and functionality of the protein is still not clear [15].
###end p 66
###begin title 67
Arginine390Histidine (R390H)
###end title 67
###begin p 68
###xml 55 56 55 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
The residue is located in the conserved alpha helix K [8]. It forms the consensus sequence, GluXXArg, which is absolutely conserved among all members of the cytochrome P450 super family [12]. Arg390 and Glu387 are one helical turn apart and are predicted to form a salt bridge. The parallel orientation of their side chains is more transparent in the three-dimensional model. Conservation of this motif indicates that it is essential for the normal function of the P450 molecule. However, the exact function is still unclear [12].
###end p 68
###begin title 69
Discussion
###end title 69
###begin p 70
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
PCG is a clinically and genetically heterogeneous disorder. In familial cases, PCG is usually autosomal recessive. Recent genetic studies from India, Saudi Arabia, and Brazil reported several mutations in the coding region of CYP1B1. More than 40 different mutations have been reported in the entire coding region of CYP1B1 [18-20], and genetic heterogeneity varies with the population. The Slovak Gypsy population showed allelic homogeneity and phenotypic uniformity [21] while other population studies reported high clinical and allelic heterogeneity. Among these groups, higher homogeneity was present in the Saudi Arabian population (with 72% having the p.G61E allele and 12% the p.R469W allele) [19] whereas other populations demonstrated increased genetic heterogeneity. High homogeneity reflects the higher rate of inbreeding in the population.
###end p 70
###begin p 71
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 1411 1412 1411 1412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1610 1612 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1156 1164 <span type="species:ncbi:9606">patients</span>
###xml 1281 1285 <span type="species:ncbi:10090">mice</span>
CYP1B1 codes for a 543 amino acid protein and is expressed in the ocular tissues, in the anterior chamber of eye, and in non-ocular tissues like the kidney and liver [22]. CYP1B1 is a member of the cytochrome P450 super family of drug metabolizing enzymes. It catalyzes several oxidative reactions, some of which are biosynthetic, producing necessary hormones or compounds of intermediary metabolism in most living organisms [23]. It acts on a wide range of substrates including many xenobiotics, vitamins, and steroids. Reactions catalyzed by the enzyme include hydroxylation, sulfoxidation, N-, S-, and O-dealkylations, desulfation, deamination, and reduction of azo, nitro, and N-oxide groups [24]. It also metabolizes vitamin A in two steps to all-trans-retinal and all-trans-retinoic acid. The latter is a potent morphogen and regulates in utero development of tissue growth and differentiation [25-27]. It is involved in the metabolism of the endogenous and exogenous substrates that take part in early ocular differentiation. Any mutation in this gene can thus cause ocular development defects and result in trabecular dysgenesis as was seen in our patients on an ultrastructural study (unpublished).The same morphological alterations have been reported in CYPIB1-deficient mice [28]. Membrane-bound cytochromes such as CYP1B1 have molecular structures containing a transmembrane domain located at the NH2-terminal end of the molecule. This is followed by a proline-rich "hinge" region, which permits flexibility between the membrane-spanning domain and the cytoplasmic portion of the protein molecule [29]. The COOH-terminal ends are highly conserved among different members of the cytochrome P450 super family. They contain a set of conserved core structures (CCS) responsible for the heme-binding region of these molecules. The heme-binding region is essential for the normal function of every P450 molecule. Between the hinge region and the CCS lies a less conserved substrate-binding region. The cytochrome P450 protein functions like any classical enzyme molecule.
###end p 71
###begin p 72
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 641 643 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
Mutations affecting such enzymes generally produce recessive phenotypes because in heterozygous subjects, the normal allele is capable of compensating for the mutant allele. Mutations in CYP1B1 interfere with the integrity of the CYP1B1 molecule as well as its ability to adopt normal conformation and to bind heme, for example, induced mutations in the hinge region have previously been reported to interfere with the heme-binding properties of the cytochrome P450 molecules [25,26]. CYP1B1 participates in the normal development and functioning of the eye by metabolizing essential molecules that are probably used in a signaling pathway [26]. Thus, normal development and differentiation of the anterior segment is important for normal ocular function, and mutations in CYPIB1 result in the malformation of anterior chamber structures, which dramatically affect visual function by blocking aqueous outflow.
###end p 72
###begin p 73
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYPIB1</italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 512 518 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 566 572 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 937 939 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 356 361 <span type="species:ncbi:9606">human</span>
###xml 458 463 <span type="species:ncbi:10090">mouse</span>
###xml 473 476 <span type="species:ncbi:10116">rat</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
CYPIB1 was originally identified as a dioxin-responsive cDNA clone, and its activity against various xenobiotics and pro-carcinogens has been intensively investigated [30]. A novel TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) responsive cDNA isolated from a human keratinocyte line has been identified as a new cytochrome P450 super family member [31]. This human protein was designated as cytochrome P450 (CYP1B1). It has also been identified and cloned from mouse [32] and rat [33]. The estimated size of rodent CYP1B1 mRNA (5.2 kb) is nearly identical to the human CYP1B1 mRNA (5.1 kb), and each predicts a protein of 543 amino acids. CYP1B1 is constitutively expressed in the adrenals, ovary, and testis and is inducible by planar aromatic hydrocarbons, adrenocorticotropin, and peptide hormones [31,34]. It is involved in the metabolism of xenobiotics and possibly steroid hormones as suggested by its tissue distribution pattern [34,35].
###end p 73
###begin p 74
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 754 760 754 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYPIB1</italic>
###xml 775 779 775 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 874 876 874 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 235 242 <span type="species:ncbi:9606">patient</span>
###xml 389 396 <span type="species:ncbi:9606">patient</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
In our study, 18% cases harbored the Ter@223 mutation. This mutation has been reported previously from southern India [8]. Earlier studies showed a very severe phenotype and poor prognosis with the Ter@223 mutation. In this study, one patient (PCG 017) was homozygous for the mutation, and two (PCG 034 and PCG 041) were compound heterozygotes for the Ter@223 and R390H mutations, and one patient (PCG 039) was a compound heterozygote for the Ter@223 and R368H mutations. Five patients (PCG 019, PCG 021, PCG 029, PCG 040, and PCG 044) were heterozygous for the Ter@223 mutation mutation. Congenital glaucoma is known to be an autosomal recessive disorder, but it is difficult to explain the disease pathogenesis in these five patients. Variants in both CYPIB1 and myocilin (MYOC) have been detected in PCG, indicating higher complexity in the pathogenesis of this disease [36]. We have already screened these cases for mutations in MYOC (unpublished). These cases did not harbor any mutations in the myocilin gene. It is possible that these cases harbor some mutations at some other loci that have yet to be identified.
###end p 74
###begin p 75
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 1719 1725 1719 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 1151 1159 <span type="species:ncbi:9606">patients</span>
###xml 1352 1360 <span type="species:ncbi:9606">patients</span>
###xml 1672 1680 <span type="species:ncbi:9606">patients</span>
All patients with a CYP1B1 mutation had the p.L432V polymorphism, and it has been reported that the CYP1B1 protein with valine at position 432 generates more free radicals and causes oxidative damage to retinal pigment epithelial cells [37]. In five patients (PCG 019, PCG 021, PCG 029, PCG 040, and PCG 044) who had the Ter@223 heterozygous mutation, we can hypothesize that in these cases, one truncated CYP1B1 protein is produced, which is a functionally null protein, and that the second allele produces a protein, which generates high reactive oxygen species (ROS) levels and thus causes oxidative stress-induced neural degeneration. Neural crest cells appear to be a particularly vulnerable cell population and are easily killed by compounds such as retinoic acid [38]. It has also been reported that developing neural crest cells are deficient in glutathione and catalase, two important antioxidant enzymes [39] that are responsible for scavenging free radicals that damage cells. Therefore, it is possible that the developing trabecular meshwork suffers oxidative damage, which may be the underlying mechanism for trabecular dysgenesis. Three patients (PCG 034, PCG 041, and PCG 039) had Ter@223 (heterozygous) with R390H and R368H mutations, and this combination may produce one functionally null protein and one defective CYP1B1 protein. All patients with Ter@223 (homozygote) and Ter@223 with p. R390H/R368H (compound heterozygote) mutations showed no perception of light even after glaucoma surgery. Little improvement in vision (light perception only) following glaucoma surgery was observed in all five cases with heterozygous Ter@223 mutation whereas other patients with homozygous/compound heterozygote CYP1B1 mutations showed no improvement at all.
###end p 75
###begin p 76
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 486 494 <span type="species:ncbi:9606">Patients</span>
###xml 576 584 <span type="species:ncbi:9606">patients</span>
###xml 612 620 <span type="species:ncbi:9606">Patients</span>
###xml 692 699 <span type="species:ncbi:9606">patient</span>
In our study, p.R390H is the second most common mutation found in 16% of patients. This mutation had been reported in other populations [13]. But p.R390H is not reported from the southern Indian population. Mutations at position 390 emerged as a hot spot for mutations in CYP1B1. Mutations p.R390H, p.R390C, and p.R390S have been reported from different populations [13]. Earlier studies showed that prognosis of patients with a p.R390H mutation is poorer than with a p.R390C mutation. Patients with the p. R390H mutation showed little or no improvement in vision compared to patients with the p.R390C mutation. Patients with the p.R368H homozygous mutation had no light perception while one patient with the R368H heterozygous mutation showed little improvement in vision following surgery.
###end p 76
###begin p 77
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 41 45 <span type="species:ncbi:9606">girl</span>
One patient (PCG 022) was a 10-month-old girl from a non-consanguineous Hindu family who harbored a p.L24R mutation. She had bilateral buphthalmos with raised intraocular pressure (IOP) in both eyes (left; 24 mmHg and right; 30 mmHg). The corneal diameter was 15 mm x 15 mm in the left eye and 16 mm x 16 mm in the right eye with a cup:disc ratio of 0.5:1 and 0.6:1 in the left and right eye, respectively. She underwent bilateral trabeculotomy and trabeculectomy twice within a period of four months and is able to fix onto and follow light.
###end p 77
###begin p 78
###xml 30 49 30 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus magaterium</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 453 460 <span type="species:ncbi:9606">patient</span>
Three-dimensional models from Bacillus magaterium (CYP108 and CYP102 protein) were used in earlier studies to determine the structure of the CYP1B1 protein, and these studies showed that the first 49 amino acids were not conserved in the protein from the cytochrome 450 families [14]. Multi-alignment of different CYP1B1 proteins showed that leucine is conserved at position 24 and may play a significant role in protein functioning [Figure 1]. Another patient (PCG 022) with the CYP1B1 p.L24R mutation only had bilateral buphthalmos with raised intraocular pressure. It is possible that p.L24R is a pathogenic mutation that shows improvement post-surgery and thus has a good prognosis, though further functional studies are required to ascertain the pathogenic role of the p. L24R mutation.
###end p 78
###begin p 79
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 63 68 <span type="species:ncbi:9606">child</span>
###xml 330 337 <span type="species:ncbi:9606">patient</span>
###xml 492 499 <span type="species:ncbi:9606">patient</span>
Patient (PCG042) harbored p.F190L mutation, was a five-day-old child from a non-consanguineous Muslim family with bilateral buphthalmos at birth with raised IOP (22 mmHg in both eyes) and corneal diameter of 13 mm x 13 mm with severe bilateral corneal edema. Fundus examination was not possible because of the corneal edema. This patient was heterozygous for the p.R368H (homozygous) and p.F190L mutations. Due to compound heterozygous status, a defective CYP1B1 protein is produced, and the patient showed no improvement in vision following surgery.
###end p 79
###begin p 80
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 8 15 <span type="species:ncbi:9606">patient</span>
Another patient (PCG 043) had congenital glaucoma at birth with IOPs of 22 and 26 mmHg in the right and left eye, respectively, with corneal diameter of 12 mm x 12.5 mm with presence of Haab's striae in both eyes. She was a compound heterozygote for the p.G329D (heterozygous) and p.R390H (heterozygous) mutations. It has been previously reported [13] that the p.R390H mutation produces a defective CYP1B1 protein as the glycine residue is conserved at this position in the alpha I helix, thus a nucleotide change at this locus can create a defective protein. Since congenital glaucoma is an autosomal recessive disorder and both mutations are heterozygous in this case, we can say that the combination of both mutations produces a defective protein, which is unable to perform its function. Hence, we can say p.G329D is a pathogenic mutation.
###end p 80
###begin p 81
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 403 409 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 460 466 460 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 514 520 514 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 620 626 620 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
In our study, 46% of patients harbored CYP1B1 mutations. This is slightly higher than the southern Indian population (43.5%) but lower than the Slovak gypsy population (100%) [7,21]. Both p.G61E and p.P193L mutations were not present in our population while these were present in congenital glaucoma patients from southern India [8]. We found no significant differences between patients with homozygous CYP1B1 mutations and patients with compound heterozygote CYP1B1 mutations. However, patients with heterozygous CYP1B1 mutations had a better prognosis after surgery than patients with homozygous/compound heterozygous CYP1B1 mutations.
###end p 81
###begin p 82
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 521 529 521 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
The mutation spectrum of northern Indian congenital glaucoma patients is totally different from the mutation spectrum of southern Indian patients. The most prevalent mutation, p. R368H, in the southern population is present in only 8% (4/50) of our patients while other mutations like p.Ter@223 and p.R390H emerged as the most prevalent CYP1B1 mutation in northern Indian patients. This difference in the mutation spectrum of both the populations may be explained on the basis of different ethnicity of both populations (Figure 1). The northern Indian population is predominantly Aryan population while the southern Indian population is Dravidian with totally different morphological phenotype and genetic background.
###end p 82
###begin p 83
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 557 563 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
Three novel mutations were identified in this study. Studies of pathogenic sequence variants of CYP1B1 in different populations may contribute to a better insight into the molecular pathogenesis of congenital glaucoma. The new mutations found in our study as well as those already reported could also add to the existing repertoire of the SNPs, which can be used in the future as diagnostic or prognostic markers for detection and to chart the path of disease progression. This will further help in the elucidation of the structure-function relationship of CYP1B1 and hence may lead to the development of novel therapeutics in management of congenital glaucoma in familial cases.
###end p 83
###begin title 84
Acknowledgments
###end title 84
###begin p 85
###xml 32 40 <span type="species:ncbi:9606">patients</span>
The authors are grateful to all patients and their family members for their participation in this study. We sincerely thank the staff of the Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS without whom this study would not be possible. This work was financed by the Department of Biotechnology. The author, M.T., also thanks the University Grants Commission (UGC) for providing Senior Research Fellowship (SRF).
###end p 85
###begin title 86
References
###end title 86
###begin article-title 87
Molecular genetics of primary congenital glaucoma.
###end article-title 87
###begin article-title 88
Population genetical aspects of primary congenital glaucoma. I. Incidence, prevalence, gene frequency, and age of onset.
###end article-title 88
###begin article-title 89
Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21.
###end article-title 89
###begin article-title 90
Population-based assessment of childhood blindness in southern India.
###end article-title 90
###begin article-title 91
Assignment of a locus (GLC3A) for primary congenital glaucoma (buphthalmos) to 2p21and evidence for genetic heterogeneity.
###end article-title 91
###begin article-title 92
A second locus (GLC3B) for primary congenital glaucoma (buphthalmos) maps to the 1p36 region.
###end article-title 92
###begin article-title 93
Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia.
###end article-title 93
###begin article-title 94
Identification of novel mutations causing familial primary congenital glaucoma in Indian pedigrees.
###end article-title 94
###begin article-title 95
Identification of a single ancestral CYP1B1 mutation in Slovak gypsies (Roms) affected with primary congenital glaucoma.
###end article-title 95
###begin article-title 96
Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novoevents and a dominant modifier locus.
###end article-title 96
###begin article-title 97
The Indian Genome Variation database (IGVdb): a project overview.
###end article-title 97
###begin article-title 98
Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1.
###end article-title 98
###begin article-title 99
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Screening of common CYP1B1 mutations in Iranian POAG patients using a microarray-based PrASE protocol.
###end article-title 99
###begin article-title 100
###xml 122 128 <span type="species:ncbi:9606">humans</span>
Disease causing mutations in proteins: Structural analysis of the CYP1B1 mutations causing primary congenital glaucoma in humans.
###end article-title 100
###begin article-title 101
Characterization of biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma.
###end article-title 101
###begin article-title 102
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Novel Cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients with Primary Congenital Glaucoma.
###end article-title 102
###begin article-title 103
Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus.
###end article-title 103
###begin article-title 104
Primary congenital glaucoma: three case reports on novel mutations and combinations of mutations in the GLC3A (CYP1B1) gene.
###end article-title 104
###begin article-title 105
Molecular genetics of primary congenital glaucoma in Brazil.
###end article-title 105
###begin article-title 106
###xml 50 58 <span type="species:ncbi:9606">Patients</span>
Correlations of Genotype with Phenotype in Indian Patients with Primary Congenital Glaucoma.
###end article-title 106
###begin article-title 107
Identification of a single ancestral CYP1B1 mutation in Slovak gypsies (Roms) affected with primary congenital glaucoma.
###end article-title 107
###begin article-title 108
###xml 28 33 <span type="species:ncbi:9606">Human</span>
Complete cDNA Sequence of a Human Dioxin-inducible mRNA Identifies a New Gene Subfamily of Cytochrome P450 That Maps to Chromosome 2.
###end article-title 108
###begin article-title 109
###xml 45 50 <span type="species:ncbi:9606">human</span>
17beta -Estradiol hydroxylation catalyzed by human cytochrome P450 lBl.
###end article-title 109
###begin article-title 110
###xml 110 117 <span type="species:ncbi:4097">tobacco</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes.
###end article-title 110
###begin article-title 111
###xml 79 84 <span type="species:ncbi:9606">human</span>
Biosynthesis of all trans-retinol: catalysis of all-trans-retinol oxidation by human p-450 cytochrome.
###end article-title 111
###begin article-title 112
Retinoid metabolizing enzymes in development.
###end article-title 112
###begin article-title 113
Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that affect growth, homeostasis, differentiation and neuroendocrine functions.
###end article-title 113
###begin article-title 114
Role of CYP1B1 in glaucoma.
###end article-title 114
###begin article-title 115
Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s.
###end article-title 115
###begin article-title 116
###xml 48 53 <span type="species:ncbi:9606">human</span>
Activation of chemically diverse carcinogens by human cytochrome P4501B1.
###end article-title 116
###begin article-title 117
###xml 28 33 <span type="species:ncbi:9606">human</span>
Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2.
###end article-title 117
###begin article-title 118
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. Cloning, sequence determination, and tissue expression.
###end article-title 118
###begin article-title 119
###xml 20 23 <span type="species:ncbi:10116">rat</span>
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Identification of a rat adrenal cytochrome P450 active in polycyclic hydrocarbon metabolism as rat CYP1B1. Demonstration of a unique tissue- specific pattern of hormonal and aryl hydrocarbon receptor- linked regulation.
###end article-title 119
###begin article-title 120
###xml 59 62 <span type="species:ncbi:10116">rat</span>
A novel adrenocorticotropin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism
###end article-title 120
###begin article-title 121
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat CYP1B1: an adrenal cytochrome P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals
###end article-title 121
###begin article-title 122
Myocilin gene implicated in primary congenital glaucoma.
###end article-title 122
###begin article-title 123
Variation Consortium TI, Ray K. Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma.
###end article-title 123
###begin article-title 124
Teratogens and craniofacial malformations: relationships to cell death.
###end article-title 124

